Skip to main content
. 2019 Aug 25;2019:9182476. doi: 10.1155/2019/9182476

Figure 3.

Figure 3

Normalized tumor volume for each group of mice in the pretargeted huA33-TCO/177Lu-DOTA-PEG7-Tz radioimmunotherapy study. The two control groups received either huA33-TCO (blue) or Tz radioligand (red) only. The three treatment groups received huA33-TCO followed 24 h later by 18.5 (green), 37.0 (purple), or 55.5 (orange) MBq of 177Lu-DOTA-PEG7-Tz. Striking differences were observed between treatment and control groups [40].